Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1017-1021. doi: 10.1051/medsci/2019201. Epub 2020 Jan 6.

[Monoclonal antibodies: also for dermatologists!]

[Article in French; Abstract available in French from the publisher]

Author information

1
Univ Montpellier, Département de dermatologie, Hôpital Saint-Eloi, CHU de Montpellier, 80 avenue Augustin Fliche, 34295 Montpellier, France - Inserm 1058, Pathogenèse et contrôle des infections chroniques (PCCI), 34394 Montpellier, France.

Abstract

in English, French

Therapeutic monoclonal antibodies are henceforth commonly used in the management of psoriasis but have been also used more recently in chronic spontaneous urticaria and atopic dermatitis. Three examples are developed herein: dupilumab, omalizumab and lanadelumab. The specificity of their mechanism of action results from a better understanding of the inflammatory pathways in these chronic diseases, which previously shared either the same targeted topical or systemic treatments. However, their high costs should be put into perspective with the epidemiology, the precise evaluation of the severity, the optimization of first line treatments and the long-term benefit/risk ratio.

PMID:
31903911
DOI:
10.1051/medsci/2019201

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center